AIM ImmunoTech Inc (AIM) FinancialsAIMAIM ImmunoTech Inc

Evaluating the bottom line, AIM ImmunoTech Inc maintains a gross margin of 80.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13511.54%, while the net margin is -14569.23%. These profitability ratios, combined with a Return on Equity (ROE) of -2382.30%, provide a clear picture of how effectively AIM converts its operational activities into shareholder value.

In the context of the broader market, AIM competes directly with industry leaders such as SKYE and ALZN. With a market capitalization of $7.87M, it holds a significant position in the sector. When comparing efficiency, AIM's gross margin of 80.77% stands against SKYE's N/A and ALZN's N/A. Such benchmarking helps identify whether AIM ImmunoTech Inc is trading at a premium or discount relative to its financial performance.

AIM has reported a gross margin of 80.77% in Q2 2026, which is strong, but it also shows a net loss of approximately $3.8 million for the same quarter, reflecting ongoing financial struggles.